



ISOPP-CAPhO Symposium 2025 | Sponsored Session

SMART

Strategies for Managing ADC- Related Toxicities

in Metastatic Breast Cancer

Thursday, April 3, 2025 | 4:45 PM – 5:45 PM PT
Victoria Conference Centre, Victoria, BC



Scott Edwards, PharmD, MSc
Clinical Oncology Pharmacist Specialist,
Dr. H. Bliss Murphy Cancer Centre
St. John's, Newfoundland



Mita Manna, MD, FRCPC
Medical Oncologist,
Saskatoon Cancer Centre
Saskatoon, SK

Learning Objectives

Upon completion of this activity, participants should be able to:

- Understand key differences between the safety profiles of antibody–drug conjugates (ADCs) currently approved by Health Canada for the treatment of metastatic breast cancer, including trastuzumab emtansine, trastuzumab deruxtecan, and sacituzumab govitecan
- Integrate proactive monitoring strategies during the routine care of patients receiving ADCs
- Collaborate with the multidisciplinary team for timely management of ADC-related toxicities